Cagrilintid / Semaglutid

CagriSema — Cagrilintide / Semaglutide Combination Research Peptide

CagriSema is the co-formulated research blend of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist), both developed by Novo Nordisk. It is the first once-weekly combination of a GLP-1 and an amylin analog and is the subject of the REDEFINE 1 and REDEFINE 2 Phase 3 trial programs. The two peptides act through non-overlapping signaling pathways, which is why researchers pair them in a single vial instead of running parallel single-peptide studies.

Why Pair Cagrilintide with Semaglutide

Semaglutide (the peptide behind Ozempic and Wegovy) targets the GLP-1 receptor – an incretin pathway that amplifies insulin release and slows gastric emptying. Cagrilintide targets the amylin receptor – a parallel pathway in the brainstem and hypothalamus that regulates meal size and satiety. Because the two pathways don’t overlap, the combined signal is larger than either alone, and each peptide complements what the other does not cover.

CagriSema vs Semaglutide vs Tirzepatide

These three show up in most current metabolic-research literature, so the distinction matters.

CagriSema and tirzepatide are both “dual-mechanism” compounds, but they hit different pairs: CagriSema is amylin + GLP-1, tirzepatide is GIP + GLP-1. The SURMOUNT and REDEFINE trial programs characterize each pairing independently.

Forschungsanwendungen

CagriSema is used in studies examining:

• Combined amylin + GLP-1 signaling in a single administration
• Body-composition endpoints under dual-pathway stimulation
• Ad-libitum caloric-intake and satiety modeling
• Glycemic and blood-pressure markers in Phase 3 protocol replication (REDEFINE framework)
• Comparative research vs. GLP-1 monotherapy and vs. GIP/GLP-1 dual agonists

Technische Daten

Rekonstitution

The blend arrives as a co-lyophilized powder and is reconstituted like a single-peptide vial:

Gesamtmenge in mg im Fläschchen ÷ hinzugefügte Wassermenge in ml = mg pro ml

Example: a 5/5mg vial (10mg total peptide) + 2mL of bacteriostatic water = 5mg per mL of total blend, which delivers 2.5mg cagrilintide and 2.5mg semaglutide per mL.

Nach der Zubereitung bei 2–8 °C lagern und innerhalb von 28–30 Tagen verbrauchen.

Anmerkungen zum Protokoll

The following values are reference points extracted from the REDEFINE 1 and REDEFINE 2 Phase 3 trials and other published CagriSema research – not instructions. Published trials escalate both peptides in parallel, in a stepwise pattern, over several weeks.

• Starting doses reported in REDEFINE: 0.25mg cagrilintide + 0.25mg semaglutide per administration
• Escalation pattern observed: Parallel stepwise escalation over ~16-20 weeks to trial-maximum doses of ~2.4mg each
• Administration frequency in published trials: Once weekly
• Study durations reported: 68 weeks in REDEFINE 1 / REDEFINE 2

Common Questions About CagriSema Research

How is CagriSema different from semaglutide alone?

CagriSema adds cagrilintide (an amylin analog) to semaglutide. Semaglutide on its own works through a single pathway (GLP-1). CagriSema works through two non-overlapping pathways (amylin + GLP-1), which is why the combined trial endpoints are larger than semaglutide monotherapy endpoints.

Is CagriSema a GLP-1?

It contains one. CagriSema is a combination of semaglutide (a GLP-1 receptor agonist) and cagrilintide (an amylin analog). It is not a single peptide – it is two peptides co-formulated in one vial.

How does CagriSema compare to tirzepatide?

They are both dual-mechanism compounds but hit different receptor pairs. CagriSema pairs an amylin analog with a GLP-1 agonist. Tirzepatide is a single molecule that activates GLP-1 and GIP. A head-to-head trial (Novo Nordisk’s REDEFINE 4 / Eli Lilly’s SURMOUNT-5 framework) has been the subject of ongoing comparative research.

Is CagriSema FDA approved?

Novo Nordisk has filed for FDA approval of CagriSema (2026). At the time of writing it is not approved for any human use. Every vial WWP ships is labeled and sold strictly for laboratory and research use only.

How is the blend stored?

Ungeöffnete Fläschchen werden bei 2–8 °C gelagert und sind mindestens 12 Monate haltbar. Nach der Rekonstitution mit bakteriostatischem Wasser wird die Lösung bei 2–8 °C aufbewahrt und innerhalb von 28–30 Tagen verbraucht.

Reinheitsgarantie

Jede Charge weist eine Reinheit von ≥99 % auf. Senden Sie uns ein Analysezertifikat einer unabhängigen Prüfstelle, und wir stellen Ihnen unabhängig vom Ergebnis eine Gutschrift aus.